Navigation Links
Watson Says Appeals Court Affirms Concerta(R) Patent Invalid

MORRISTOWN, N.J., April 26 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the U.S. Court of Appeals for the Federal Circuit Court has affirmed a March 31, 2009 District Court decision that the asserted claims of ALZA's United States Patent No. 6,919,373 "the '373 Patent" are invalid.  The original suit by ALZA Corporation and McNeil-PPC, Inc. alleged that Watson's generic versions of Concerta® (methylphenidate hydrochloride extended-release tablets), developed by Watson's subsidiaries, Andrx Corporation and Andrx Pharmaceuticals LLC, infringed the '373 Patent.  The opinion, dated April 26, 2010, applies to Watson's generic versions of Concerta® in the 18 mg, 27 mg, 36 mg and 54 mg strengths.  

Watson noted that the Appeals Court decision addresses patent infringement questions concerning its methylphenidate ER tablets, a generic version of Concerta®.  FDA must resolve a Citizen Petition, and approve Watson's pending Abbreviated New Drug Application (ANDA), prior to launch of its generic.  Concerta® has annual brand sales of approximately $1.2 billion.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts and FDA approvals or actions, if any; the difficulty of predicting the timing or outcome of litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Concerta® is a registered trademark of ALZA Corporation.


SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
(Date:10/12/2015)... Oct. 12, 2015 CorVascular Diagnostics, ... medical technology company that designs and distributes ... it has entered into a collaboration and ... dedicated to producing devices, software and services ... PAD-IQ®, developed and produced by Vasamed, provides ...
(Date:10/12/2015)... St. Paul, Minn. , Oct. 12, 2015 /PRNewswire/ ... with it, a need to help integrate these devices ... global leader of ergonomic healthcare mounting and mobility solutions, ... Carts, its lightest cart yet, for a wide array ... StyleView S-Tablet Cart SV10 was developed exclusively for Microsoft ...
(Date:10/12/2015)... 12, 2015 Beginning October 1, 2015 All ... the fastest growing practice management system for therapists, psychologists, ... converts all patient diagnostic codes from the former DSM-4/ICD-9, ... --> --> Therapy Partner has also ... health practitioners to easily understand the conversion to ICD-10 ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, ... Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will take ... and will unite customers, partners, WennSoft team members and sponsors to facilitate the ...
(Date:10/13/2015)... ... , ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, ... for more than 5 years. A leading cause of emergency room visits, school ... is not timely. , Sedation dentistry provides an anxiety-free dental experience ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... activities. Yet most people do not breathe correctly. According to T’ai Chi (also ... Steve Lauer, learning to breathe correctly, in concert with the 7,000 year old ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... communities, and the Florida Apartment Association (FAA) has partnered with the Florida Department ... meet the demand. , The FAA Smoke-Free Multifamily Housing Program launched last ...
(Date:10/13/2015)... ... , ... Curly Hair Solutions® is thrilled to be a ... featuring the newest products and services to hit the market for women. With ... to unveil their recent partnership with Trade Secrets, a leading Canadian beauty retailer. ...
Breaking Medicine News(10 mins):